154 related articles for article (PubMed ID: 1465751)
1. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.
Gallacher SJ; Fenner JA; Anderson K; Bryden FM; Banham SW; Logue FC; Cowan RA; Boyle IT
Thorax; 1992 Nov; 47(11):932-6. PubMed ID: 1465751
[TBL] [Abstract][Full Text] [Related]
2. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
3. [Cyclic intravenous pamidronate in treatment of osteoporosis].
Vujasinović-Stupar N; Pilipović N; Branković S
Med Pregl; 2004; 57(11-12):545-50. PubMed ID: 16107000
[TBL] [Abstract][Full Text] [Related]
4. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation.
Reeves HL; Francis RM; Manas DM; Hudson M; Day CP
Liver Transpl Surg; 1998 Sep; 4(5):404-9. PubMed ID: 9724478
[TBL] [Abstract][Full Text] [Related]
5. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause.
Thiébaud D; Burckhardt P; Melchior J; Eckert P; Jacquet AF; Schnyder P; Gobelet C
Osteoporos Int; 1994 Mar; 4(2):76-83. PubMed ID: 8003844
[TBL] [Abstract][Full Text] [Related]
6. Effects of 3 years of intravenous pamidronate treatment on bone markers and bone mineral density in a patient with osteoporosis-pseudoglioma syndrome (OPPG).
Bayram F; Tanriverdi F; Kurtoğlu S; Atabek ME; Kula M; Kaynar L; Keleştimur F
J Pediatr Endocrinol Metab; 2006 Mar; 19(3):275-9. PubMed ID: 16607930
[TBL] [Abstract][Full Text] [Related]
7. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study.
Krieg MA; Seydoux C; Sandini L; Goy JJ; Berguer DG; Thiébaud D; Burckhardt P
Osteoporos Int; 2001; 12(2):112-6. PubMed ID: 11303710
[TBL] [Abstract][Full Text] [Related]
8. Cyclical pamidronate infusions in postmenopausal osteoporosis.
Peretz A; Body JJ; Dumon JC; Rozenberg S; Hotimski A; Praet JP; Moris M; Ham H; Bergmann P
Maturitas; 1996 Aug; 25(1):69-75. PubMed ID: 8887311
[TBL] [Abstract][Full Text] [Related]
9. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial.
Boutsen Y; Jamart J; Esselinckx W; Stoffel M; Devogelaer JP
Calcif Tissue Int; 1997 Oct; 61(4):266-71. PubMed ID: 9312195
[TBL] [Abstract][Full Text] [Related]
10. Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate.
Landman JO; Hamdy NA; Pauwels EK; Papapoulos SE
J Clin Endocrinol Metab; 1995 Dec; 80(12):3465-8. PubMed ID: 8530584
[TBL] [Abstract][Full Text] [Related]
11. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
12. Intravenous pamidronate in juvenile osteoporosis.
Shaw NJ; Boivin CM; Crabtree NJ
Arch Dis Child; 2000 Aug; 83(2):143-5. PubMed ID: 10906023
[TBL] [Abstract][Full Text] [Related]
13. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis.
Cauza E; Etemad M; Winkler F; Hanusch-Enserer U; Partsch G; Noske H; Dunky A
J Clin Pharm Ther; 2004 Oct; 29(5):431-6. PubMed ID: 15482386
[TBL] [Abstract][Full Text] [Related]
14. Intravenous pamidronate in the treatment and prevention of osteoporosis.
Chan SS; Nery LM; McElduff A; Wilmshurst EG; Fulcher GR; Robinson BG; Stiel JN; Gunton JE; Clifton-Bligh PB
Intern Med J; 2004 Apr; 34(4):162-6. PubMed ID: 15086695
[TBL] [Abstract][Full Text] [Related]
15. Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis.
Heijckmann AC; Juttmann JR; Wolffenbuttel BH
Neth J Med; 2002 Sep; 60(8):315-9. PubMed ID: 12481878
[TBL] [Abstract][Full Text] [Related]
16. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis.
Reid IR; Wattie DJ; Evans MC; Gamble GD; Stapleton JP; Cornish J
J Clin Endocrinol Metab; 1994 Dec; 79(6):1595-9. PubMed ID: 7989461
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation.
Aris RM; Lester GE; Renner JB; Winders A; Denene Blackwood A; Lark RK; Ontjes DA
Am J Respir Crit Care Med; 2000 Sep; 162(3 Pt 1):941-6. PubMed ID: 10988110
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with pamidronate in the treatment of Paget's disease of bone.
Gallacher SJ; Boyce BF; Patel U; Jenkins A; Ralston SH; Boyle IT
Ann Rheum Dis; 1991 Dec; 50(12):930-3. PubMed ID: 1768163
[TBL] [Abstract][Full Text] [Related]
19. Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis.
Morabito N; Gaudio A; Lasco A; Vergara C; Tallarida F; Crisafulli G; Trifiletti A; Cincotta M; Pizzoleo MA; Frisina N
Osteoporos Int; 2003 Jul; 14(6):500-6. PubMed ID: 12750879
[TBL] [Abstract][Full Text] [Related]
20. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
Stokkers PC; Deley M; Van Der Spek M; Verberne HJ; Van Deventer SJ; Hommes DW
Scand J Gastroenterol; 2006 Feb; 41(2):200-4. PubMed ID: 16484125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
